Topical-Lingual Semaglutide for Obesity
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Gila Therapeutics, Inc. · Industry
This trial is looking for adults with obesity who want to try a new way to take a medication that might help with weight management. Participants will take a special liquid form of the drug semaglutide to see if it can help reduce weight.
You may be able to join if
- I have a Body Mass Index (BMI) between 30 and 45.
You may not be able to join if
- I have type 2 diabetes.
- I have Multiple Endocrine Neoplasia Type 2.
- I have had medullary thyroid cancer.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Loading trial locations…
No contact information available.